Accueil  >  

Tag: Réduction des méfaits

 

INHSU 2019: Wholistic hepatitis C care, and the importance of care providers

 28 novembre 2019 •  Par April Mazzuca

Hundreds of clinicians, researchers and people with lived experience gathered in Montreal in September 2019 to highlight promising work in hepatitis C research and practice. The 8th International Conference on Hepatitis Care in Substance Users (INHSU 2019) showcased innovative models of care that support the delivery of hepatitis C treatment. A major theme emerging from this work was the need for wholistic* models of care, moving beyond hepatitis C treatment and toward the integration of services attending to the emotional, physical, mental and spiritual health needs of people who use drugs. Community involvement in development and delivery of wholistic models...

Pour en savoir plus...
 

Meeting people where they are is about much more than location: Delivering hepatitis C care and treatment to people who use drugs

 14 octobre 2019 •  Par Tracy Swan

Poverty, stigma and criminalization are chronic problems among people who use and inject drugs. But hepatitis C virus (HCV) is no longer such a problem, since it is usually cured by eight to 12 weeks of oral, direct-acting antivirals (DAAs). Delivering DAAs to people who use and inject drugs in the context of the chronic problems facing them is an opportunity to recognize and support the contribution of people with lived experience, and to build and strengthen systems and programs. These systems and programs must provide welcoming, respectful and safe spaces for people who use and inject drugs, as they...

Pour en savoir plus...
 

Modèle directeur pour guider les efforts d’élimination de l’hépatite C au Canada : Une approche basée sur les populations prioritaires et l’équité en matière de santé – Deuxième partie

 29 août 2019 •  Par Jennifer Broad, Sandra Ka Hon Chu, Lindsay Jennings

Ce billet de blogue est un suivi d’un autre billet qui a été publié le 27 août, 2019 sur le Modèle directeur pour guider les efforts d’élimination de l’hépatite C au Canada. 

Pour en savoir plus...
 

Can Halifax open Atlantic Canada’s first legal overdose prevention site? Yes, we can!

 14 août 2019 •  Par Matthew Bonn

This blog post is a follow-up from an earlier post published on July 11, 2019. As I work on a new funding proposal, this statement strikes me: over 11,500 people in Canada have lost their lives as a result of opioid-related overdoses between January 2016 and December 2018 and we keep losing people every day. So many lives lost! And why is that? The evidence is clear that overdose prevention sites save lives! After I returned from a hands-on training in the Downtown East Side of Vancouver, one of the hardest hit places in the overdose crisis, it became even...

Pour en savoir plus...
 

L’hépatite C : Y aura-t-il 40 ans entre sa découverte et son élimination?

 3 juillet 2019 •  Par Melisa Dickie

Nous sommes au cœur d’une période incroyablement dynamique dans le monde de la médecine et de la santé publique. La recherche dans le domaine de l’hépatite C a progressé si rapidement que le virus pourrait être éliminé comme menace pour la santé publique seulement 40 ans après sa découverte en 1989.

Pour en savoir plus...